Blinatumomab: Enlisting serial killer T-cells in the war against hematologic malignancies

Expert Opinion on Biological Therapy

Volumn 15, Issue 6, 2015, Pages 895-908

  Rogala, Britny ^a   Freyer, Craig W ^a   Ontiveros, Evelena P ^a   Griffiths, Elizabeth A ^a   Wang, Eunice S ^a   Wetzler, Meir ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Acute lymphoblastic leukemia; AMG 103; Bi specific T cell engager; Blinatumomab; Non Hodgkin's lymphoma

Indexed keywords

BLINATUMOMAB; CHIMERIC ANTIGEN RECEPTOR; INOTUZUMAB OZOGAMICIN; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ATAXIA; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); CONFUSION; CONVULSION; CYTOKINE RELEASE SYNDROME; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN DEFICIENCY; INFECTION; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; NATURAL KILLER T CELL; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEIZURE; SPEECH DISORDER; TREATMENT RESPONSE; TREMOR; TUMOR LYSIS SYNDROME; ANIMAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; TRENDS;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84929863348     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1041912     Document Type: Article

References (69)

1. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (ASH Annual Meeting Abstracts) 2007;109:944-50
2. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116:5568-74
3. Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012;120:2032-41
4. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: A historical perspective. Pharmacol Ther 2012;136(3):334-42
5. Löffler A, Kufer P, Lutterbuse R, et al. A recombinant bispecific single-chain antibody, CD19xCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood (ASH Annual Meeting Abstracts) 2000;95(6):2098-103
6. Wolf E, Hofmeister R, Kufer P, et al. BiTEs: bispecific antibody constructs with unique anti-Tumor activity. Drug Discov Today 2005;10(18):1237-44
7. Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43:763-71
8. Löffler A, Gruen M, Wuchter C, et al. Efficient elimination of chronic lymphocytic leukemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003;17:900-9
9. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood (ASH Annual Meeting Abstracts) 2012;119(26):6226-33
10. Dreier T, Lorenczerski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100:690-7 . In vitro analysis of the pharmacokinetics and pharmacodynamics of blinatumomab.
11. Hoffman P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98-104
12. Gruen M, Bommert K, Bargou RC. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother 2004;53:625-32
13. dArgouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33(3):465-73
14. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012;1:36
15. Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 2011;52(2):325-7
16. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52(6):1098-107
17. Nagorsen D, Bargou R, Ruttinger D, et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009;50(6):886-91
18. Hijazi Y, Klinger M, Schub A, et al. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). J Clin Oncol 31, 2013(Suppl):abstract 3051
19. Brandl C, Haas C, dArgouges S, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 2007;56:1551-63
20. Blincyto- [package insert]. Amgen Inc; Thousand Oaks, CA: 2014
21. Wu B, Hijazi Y, Wolf A, et al. Pharmacokinetics (PK) of blinatumomab and its clinical implications. J Clin Oncol 31, 2013(Suppl):abstract 3048
22. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7
23. Goebeler M, Viardot A, Noppeney R, et al. Blinatumomab (CD3/CD19 BiTE- Antibody) results in high response rate in patients with relapsed non-Hodgkins lymphoma (NHL) including MCL and DLBCL. Ann Oncol 2011;22(4):abstract 068
24. Goebeler ME, Viardot A, Kufer P, et al. Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory Non-Hodgkins lymphoma. Hematol Oncol 2013;31(Suppl 1): abstract 302
25. Viardot A, Goebeler M, Nopponey R, et al. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2011;abstract 1637. Available from: https://ash.confex.com/ash/2011/webprogram/Paper36931.html
26. Viardot A, Goebeler M, Scheele J, et al. Treatment of patients with non-Hodgkin lymphoma (NHL) with CD19/CD3 bispecific antibody blinatumomab (MT103): double-step dose increase to continuous infusion of 60 μg/m2/d is tolerable and highly effective. Blood (ASH Annual Meeting Abstracts) 2010;116(21):abstract 2880
27. Viardot A, Goebeler M, Hess G, et al. Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T-cell engager (BiTE-) antibody construct blinatumomab: primary analysis results from an open-label, phase 2 study. Blood (ASH Annual Meeting Abstracts) 2014;abstract 4460. Available from: https://ash.confex.com/ash/2014/webprogram/Paper68589.html
28. Topp MS, Gökbuget N, Zugmaier G, et al. Phase II Trial of the Anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32(36):4134-40
29. Goekbuget N, Dombret H, Bonifacio M, et al. BLAST: a confirmatory, single-Arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE-) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2014;abstract 379. Available from: https://ash.confex.com/ash/2014/webprogram/Paper67851.html
30. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29(18):2493-8 . First clinical trial to assess the efficacy of blinatumomab in ALL, specifically in elimination of MRD in patients in hematologic CR.
31. Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107(3):1116-23
32. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for riskspecific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009;113(18):4153-62
33. Raff T, Gökbuget N, Luschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007;109(3):910-15
34. Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120(9):1868-76
35. Topp MS, Gökbuget N, Zugmaier et al. Long-Term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120(26): 5185-7
36. Zugmaier G, Gökbuget N, Viardot A, et al. Long-Term survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) who achieved minimal residual disease (MRD) response following anti-CD19 BiTE- blinatumomab. Blood (ASH Annual Meeting Abstracts) 2014;abstract 2287. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69269.html
37. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-Arm, phase 2 study. Lancet Oncol 2015;16:57-66
38. Stein A, Topp M, Gökbuget N, et al. allogeneic hematopoietic stem cell transplantation following anti-CD19 BiTE- blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2014;abstract 965. Available from: https://ash.confex.com/ash/2014/webprogram/Paper70180.html
39. Handgretinger R, Zugmaier G, Henze G, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-Transplant relapsed acute lymphoblastic leukemia. Leukemia 2011;25:181-4
40. Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014;99(7):1212-19
41. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) Receiving blinatumomab treatment. Blood (ASH Annual Meeting Abstracts) 2014;abstract 2292. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69576.html
42. Gore L, Locatelli F, Zugmaier G, et al. Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 2014;abstract 3703. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69686.html
43. Wong R, Pepper C, Brennan P, et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 2013;98(12):1930-8
44. Golay J, DAmico A, Borleri G, et al. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy. J Immunol 2014;193:4739-47
45. Jadidi-Niaragh F, Yousefi M, Memarian A, et al. Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression. Cancer Invest 2013;31:121-31
46. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80(2):470-7
47. Brandt JT, Tisone JA, Bohman JE, Theil KS. Aberrant expression of CD19 as a marker of monocytic lineage in acute myelogenous leukemia. Am J Clin Pathol 1997;107(3):283-91
48. Ball ED, Davis RB, Griffin JD, et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991;77(10):2242-50
49. Solary E, Casasnovas RO, Campos L, et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Leukemia 1992;6(5):393-9
50. Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014;123(4):554-61
51. Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-Term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123(3):356-65
52. Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013;27(5):1107-15
53. Bonifant CL, Torres D, Velasquez MP, et al. CD123-engager T cells as a novel immunotherapeutic for AML. Blood (ASH Annual Meeting Abstracts) 2014;abstract 3762. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69216.html
54. Smith BD, Roboz GJ, Walter RB, et al. First-in man, phase 1 study of CSL362 (Anti-IL3Ra/anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood (ASH Annual Meeting Abstracts) 2014;abstract 120. Available from: https://ash.confex.com/ash/2014/webprogram/Paper73194.html
55. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121(26):5154-7
56. Lee DW, Gardner R, Porter DL, et al. Current concepts in diagnosis and management of cytokine release syndrome. Blood 2014;124(2):188-95
57. Zugmaier G, Topp MS, Alekar S, et al. Long-Term follow-up of serum immunoglobulin levels in blinatumomabtreated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 2014;4:244
58. National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia [Version 2.2014]. [Accessed 8 Febuary 2015]
59. Duell J, Dittrich M, Bedke T, et al. Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients. Blood (ASH Annual Meeting Abstracts) 2014;abstract 2291. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69981.html
60. OBrien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosomenegative acute lymphoblastic leukemia. J Clin Oncol 2013;31(6):676-83
61. Grupp S, Maude SL, Shaw P, et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory all. Blood (ASH Annual Meeting Abstracts) 2014;abstract 380. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69932.html
62. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-17
63. Frey NV, Levine BL, Lacey SF, et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Blood (ASH Annual Meeting Abstracts) 2014;abstract 2296. Available from: https://ash.confex.com/ash/2014/webprogram/Paper76315.html
64. Brentjens R, Davila M, Riviere I, et al. CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra38
65. Park JH, Riviere I, Wang X, et al. CD19-Targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL. Blood (ASH Annual Meeting Abstracts) 2014;abstract 382. Available from: https://ash.confex.com/ash/2014/webprogram/Paper76573.html
66. Lee DW, Stetler-Stevenson M, Sabatino M, et al. Intent-To-Treat results of a phase I trial of CD19 chimeric antigen receptor T cells using a consistent treatment regimen reveals a 67% complete response rate in relapsed, refractory acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2014;124(21):abstract 381. Available from: https://ash.confex.com/ash/2014/webprogram/Paper75723.html
67. Francis J, Dharmadhikari AV, Sait SN, et al. CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. Leuk Lymphoma 2013;57(7):1517-20
68. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13(4):403-11
69. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119:2728-36